Parkinson Disease: A Review of Guidelines, Updates, and Treatment Advances

Parkinson Disease: A Review of Guidelines, Updates, and Treatment Advances

Faculty Presenters

Erica Marini, PharmD, MS, BCPS
Clinical Pharmacist, Neurology
University of Utah Health
Salt Lake City, Utah

Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP
Senior Director, Clinical Analytics
WellDyne
Tampa, Florida
 
Program Description
In recent years, there have been numerous advances in therapies for Parkinson disease (PD), but guidelines for treatment are far behind. The progressive impairment in motor functioning and worsening symptoms restricting autonomic, sensory, and neuropsychiatric functions cause significant burdens on patients’ quality of life. Although dopaminergic agents are effective for management of motor symptoms associated with PD, they do not provide neuroprotective effects or alter progression of the disease. Such agents are also associated with frequent dose-limiting adverse effects that warrant the use of adjunctive medications and compound direct medical costs. This activity will review ongoing clinical trial data for agents targeting the α-synuclein pathology associated with PD as well as new formulations with the potential to minimize motor-related complications. In the absence of long-term evidence for neuroprotection, managed care pharmacists should be able to address patient expectations regarding appropriate drug therapy, proper medication use and dosage, and current limitations of the medications available for PD.

Target audience: Specialty and managed care pharmacists, managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in the scientific advances of or involved in the care of patients with Parkinson disease.
Type of activity: Application
Release date: October 30, 2020
Expiration date: October 30, 2021
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine diagnostic considerations, approaches to therapy, and the quality of life burden of patients and caregivers in Parkinson disease (PD)
• Analyze current treatments and guidelines for PD as well as the clinical data to support new and emerging treatments
• Explore management strategies when considering access to therapies for PD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-329-H01-P. The activity is available for CE credit through October 30, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures
Erica Marini, PharmD, MS, BCPS, and Patty Taddei-Allen, PharmD, MBA, have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms